Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2020 2
2021 3
2022 3
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade.
Yang J, Yang L, Tordon B, Bucher O, Nugent Z, Landego I, Bourrier N, Uminski K, Brown K, Squires M, Marshall AJ, Katyal S, Mahmud S, Decker K, Geirnaert M, Dawe DE, Gibson SB, Johnston JB, Banerji V. Yang J, et al. Among authors: geirnaert m. Curr Oncol. 2023 Jul 5;30(7):6411-6431. doi: 10.3390/curroncol30070472. Curr Oncol. 2023. PMID: 37504332 Free PMC article.
Off-label infusion of biosimilar bevacizumab: A provincial experience.
Geirnaert M, Howarth J, Kellett C, Martin K, Streilein S, Ricard C, Wasney D, Niraula S. Geirnaert M, et al. J Oncol Pharm Pract. 2020 Oct;26(7):1683-1685. doi: 10.1177/1078155220945374. Epub 2020 Jul 29. J Oncol Pharm Pract. 2020. PMID: 32727322
International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions.
Walker A, Chan A, Labra CC, de Lemos ML, Geirnaert M, Albert-Marí MA, Atik EA, Borlagdan J, Crespo A, Danilak M, Kandemir EA, Lim C, Alabelewe RM, Mutiara R, Tewthanom K, Yim B, Nakashima L. Walker A, et al. Among authors: geirnaert m. J Oncol Pharm Pract. 2023 Jul;29(5):1065-1074. doi: 10.1177/10781552221090199. Epub 2022 Apr 5. J Oncol Pharm Pract. 2023. PMID: 35382638
Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
Parmar A, Dai WF, Dionne F, Geirnaert M, Denburg A, Ahuja T, Beca J, Bouchard S, Chambers C, Hunt MJ, Husereau D, Lungu E, McDonald V, Mercer RE, Mitera G, Muñoz C, Naipaul R, Peacock S, Potashnik T, Tadrous M, Takhar P, Taylor M, Trudeau M, Wasney D, Gavura S, Chan KKW. Parmar A, et al. Among authors: geirnaert m. Curr Oncol. 2023 Mar 28;30(4):3776-3786. doi: 10.3390/curroncol30040286. Curr Oncol. 2023. PMID: 37185399 Free PMC article.
Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia.
Bourrier N, Landego I, Bucher O, Squires M, Streu E, Hibbert I, Whiteside T, Gibson SB, Geirnaert M, Johnston JB, Dawe DE, Banerji V. Bourrier N, et al. Among authors: geirnaert m. BMC Cancer. 2022 Feb 6;22(1):148. doi: 10.1186/s12885-022-09256-2. BMC Cancer. 2022. PMID: 35123433 Free PMC article.
Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise.
Dai WF, Craig E, Fraser B, Chambers A, Mai H, Brown MB, Earle CC, Evans WK, Geirnaert M, Taylor M, Trudeau M, Sperber D, Beca JM, Denburg A, Mercer RE, Parmar A, Tadrous M, Takhar P, Chan KKW, On Behalf Of The CanREValue Collaboration. Dai WF, et al. Among authors: geirnaert m. Curr Oncol. 2021 Nov 12;28(6):4645-4654. doi: 10.3390/curroncol28060392. Curr Oncol. 2021. PMID: 34898572 Free PMC article.
12 results